Stephens Investment Management Group LLC lifted its holdings in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 55.4% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 395,281 shares of the company's stock after buying an additional 140,971 shares during the period. Stephens Investment Management Group LLC owned approximately 0.29% of Guardant Health worth $70,502,000 at the end of the most recent reporting period.
Several other large investors also recently bought and sold shares of GH. Global Retirement Partners LLC grew its position in shares of Guardant Health by 124.8% in the 3rd quarter. Global Retirement Partners LLC now owns 888 shares of the company's stock valued at $158,000 after acquiring an additional 493 shares during the period. Banco Santander S.A. bought a new stake in shares of Guardant Health in the 3rd quarter valued at about $596,000. HighTower Advisors LLC raised its holdings in shares of Guardant Health by 1.8% in the 3rd quarter. HighTower Advisors LLC now owns 22,802 shares of the company's stock valued at $4,067,000 after purchasing an additional 412 shares during the period. Intech Investment Management LLC lifted its stake in Guardant Health by 54.2% in the 3rd quarter. Intech Investment Management LLC now owns 15,138 shares of the company's stock valued at $2,700,000 after purchasing an additional 5,319 shares during the last quarter. Finally, Trillium Asset Management LLC acquired a new stake in Guardant Health in the 3rd quarter valued at about $2,181,000. 92.60% of the stock is currently owned by institutional investors.
Analyst Upgrades and Downgrades
A number of research firms recently commented on GH. BTIG Research lifted their price target on Guardant Health from $195.00 to $210.00 and gave the stock a "buy" rating in a report on Tuesday, October 27th. Royal Bank Of Canada upped their price objective on Guardant Health from $185.00 to $200.00 and gave the company an "outperform" rating in a research note on Friday, July 31st. UBS Group raised their price objective on Guardant Health from $175.00 to $225.00 and gave the company a "buy" rating in a research report on Wednesday, September 9th. Stifel Nicolaus lifted their target price on Guardant Health from $130.00 to $180.00 and gave the stock a "buy" rating in a research note on Friday, July 31st. Finally, Piper Sandler decreased their target price on Guardant Health from $193.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, November 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $190.88.
Check Out Our Latest Report on GH
Guardant Health Stock Performance
GH stock opened at $145.14 on Thursday. The company's 50-day simple moving average is $167.58 and its 200 day simple moving average is $133.48. Guardant Health, Inc. has a 52 week low of $74.55 and a 52 week high of $191.05. The company has a market capitalization of $19.64 billion, a PE ratio of -39.44 and a beta of 1.67.
Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.46. The business had revenue of $360.98 million during the quarter, compared to analyst estimates of $350.72 million. During the same quarter last year, the firm earned ($0.74) EPS. Guardant Health's revenue for the quarter was up 36.1% compared to the same quarter last year. On average, analysts forecast that Guardant Health, Inc. will post -3.28 EPS for the current year.
Insider Buying and Selling at Guardant Health
In related news, Director Alex M. Azar II sold 826 shares of the stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $175.00, for a total transaction of $144,550.00. Following the sale, the director owned 825 shares of the company's stock, valued at $144,375. This represents a 50.03% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Steve E. Krognes sold 6,674 shares of the firm's stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $175.74, for a total value of $1,172,888.76. Following the transaction, the director owned 7,906 shares in the company, valued at approximately $1,389,400.44. This trade represents a 45.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,224 shares of company stock valued at $9,116,546 in the last three months. Corporate insiders own 5.60% of the company's stock.
About Guardant Health
(
Free Report)
Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.
Read More
Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.